The efficacy of AMPK agonists including metformin, resveratrol and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) for treating mitochondrial disease has been explored with limited success and conflicting results [17–19]. Here, PRKAA1 is linked to inborn mitochondrial metabolism disorder.